{"pmid":32202401,"title":"Urology practice during COVID-19 pandemic.","text":["Urology practice during COVID-19 pandemic.","The severe acute respiratory syndrome coronavirus 2 and the disease it causes, coronavirus disease 2019 (COVID-19) is generating a rapid and tragic health emergency in Italy due to the need to provide assistance to an overwhelming number of infected patients and, at the same time, treat all the non-deferrable oncological and benign conditions. A panel of Italian urologists has agreed on possible strategies for the reorganization of urological routine practice and on a set of recommendations that should facilitate the process of rescheduling both surgical and outpatient activities during the COVID-19 pandemic and in the subsequent phases. This document could be a valid tool to be used in routine clinical practice and, possibly, a cornerstone for further discussion on the topic also considering the further evolution of the COVID-19 pandemic. It also may provide useful recommendations for national and international urological societies in a condition of emergency.","Minerva Urol Nefrol","Ficarra, Vincenzo","Novara, Giacomo","Abrate, Alberto","Bartoletti, Riccardo","Crestani, Alessandro","De Nunzio, Cosimo","Giannarini, Gianluca","Gregori, Andrea","Liguori, Giovanni","Mirone, Vincenzo","Pavan, Nicola","Scarpa, Roberto M","Simonato, Alchiede","Trombetta, Carlo","Tubaro, Andrea","Porpiglia, Francesco","32202401"],"abstract":["The severe acute respiratory syndrome coronavirus 2 and the disease it causes, coronavirus disease 2019 (COVID-19) is generating a rapid and tragic health emergency in Italy due to the need to provide assistance to an overwhelming number of infected patients and, at the same time, treat all the non-deferrable oncological and benign conditions. A panel of Italian urologists has agreed on possible strategies for the reorganization of urological routine practice and on a set of recommendations that should facilitate the process of rescheduling both surgical and outpatient activities during the COVID-19 pandemic and in the subsequent phases. This document could be a valid tool to be used in routine clinical practice and, possibly, a cornerstone for further discussion on the topic also considering the further evolution of the COVID-19 pandemic. It also may provide useful recommendations for national and international urological societies in a condition of emergency."],"journal":"Minerva Urol Nefrol","authors":["Ficarra, Vincenzo","Novara, Giacomo","Abrate, Alberto","Bartoletti, Riccardo","Crestani, Alessandro","De Nunzio, Cosimo","Giannarini, Gianluca","Gregori, Andrea","Liguori, Giovanni","Mirone, Vincenzo","Pavan, Nicola","Scarpa, Roberto M","Simonato, Alchiede","Trombetta, Carlo","Tubaro, Andrea","Porpiglia, Francesco"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202401","week":"202013|Mar 23 - Mar 29","doi":"10.23736/S0393-2249.20.03846-1","source":"PubMed","locations":["Italy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1662090442901028864,"score":6.998814,"similar":[{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment"],"weight":1,"_version_":1661359647650480128,"score":168.59883},{"pmid":32198190,"title":"Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.","text":["Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.","The coronavirus disease 2019 (COVID-19) is a zoonotic viral infection originating from Wuhan, China in December 2019. The World Health Organization has classified this pandemic as a global health emergency due to its virulent nature of transmission, which may lead to acute respiratory distress syndrome. Singapore's health ministry has responded with enhanced surveillance of COVID-19 for all suspected pneumonia cases, further increasing the volume of testing via real-time reverse transcription PCR, as well as samples necessitating stringent infectious control. Collectively, this has implications on the total testing process, laboratory operations and its personnel due to biosafety concerns. Turnaround time for routine testing may also be affected. The aim of this article is to present our tertiary institution's early experience with managing this emerging crisis and offer practical considerations for the preanalytical, analytical and postanalytical phases of laboratory testing in this cohort of patients.","J Clin Pathol","Tan, Shaun S","Yan, Benedict","Saw, Sharon","Lee, Chun Kiat","Chong, Ai Teng","Jureen, Roland","Sethi, Sunil","32198190"],"abstract":["The coronavirus disease 2019 (COVID-19) is a zoonotic viral infection originating from Wuhan, China in December 2019. The World Health Organization has classified this pandemic as a global health emergency due to its virulent nature of transmission, which may lead to acute respiratory distress syndrome. Singapore's health ministry has responded with enhanced surveillance of COVID-19 for all suspected pneumonia cases, further increasing the volume of testing via real-time reverse transcription PCR, as well as samples necessitating stringent infectious control. Collectively, this has implications on the total testing process, laboratory operations and its personnel due to biosafety concerns. Turnaround time for routine testing may also be affected. The aim of this article is to present our tertiary institution's early experience with managing this emerging crisis and offer practical considerations for the preanalytical, analytical and postanalytical phases of laboratory testing in this cohort of patients."],"journal":"J Clin Pathol","authors":["Tan, Shaun S","Yan, Benedict","Saw, Sharon","Lee, Chun Kiat","Chong, Ai Teng","Jureen, Roland","Sethi, Sunil"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198190","week":"202012|Mar 16 - Mar 22","doi":"10.1136/jclinpath-2020-206563","keywords":["chemical pathology","chemistry","infection control","laboratory management"],"source":"PubMed","locations":["Singapore","China","Wuhan"],"countries":["China","Singapore"],"countries_codes":["CHN|China","SGP|Singapore"],"weight":0,"_version_":1661900078723366914,"score":138.54063},{"pmid":32203711,"title":"Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","text":["Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality.","Lancet Respir Med","Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran","32203711"],"abstract":["WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality."],"journal":"Lancet Respir Med","authors":["Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203711","week":"202013|Mar 23 - Mar 29","doi":"10.1016/S2213-2600(20)30121-1","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1662090442966040576,"score":137.86429},{"pmid":32201335,"title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.","J Am Coll Cardiol","Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A","32201335"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems."],"journal":"J Am Coll Cardiol","authors":["Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201335","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jacc.2020.03.031","keywords":["cardiovascular therapy","coronavirus","health system"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1662090442940874752,"score":128.29324},{"pmid":32185863,"title":"Crises drive innovation.","text":["Crises drive innovation.","Crises often drive innovation. The COVID 19 pandemic has led to the necessary postponement of much planned surgical activity with the cancellation of outpatient, diagnostic and operative work. These measures have been designed to 'flatten the curve' and delay the spread of coronavirus whilst also freeing up capacity within hospitals for patients affected with the virus. This inevitable postponement of routine activity will create challenges to health care systems when normal business resumes and in many healthcare settings, which are often already resource constrained. This will impose an additional burden on patients whose diagnoses and treatment will be delayed.","Colorectal Dis","Gunner, Charlotte K","Oliphant, R","Watson, Angus Jm","32185863"],"abstract":["Crises often drive innovation. The COVID 19 pandemic has led to the necessary postponement of much planned surgical activity with the cancellation of outpatient, diagnostic and operative work. These measures have been designed to 'flatten the curve' and delay the spread of coronavirus whilst also freeing up capacity within hospitals for patients affected with the virus. This inevitable postponement of routine activity will create challenges to health care systems when normal business resumes and in many healthcare settings, which are often already resource constrained. This will impose an additional burden on patients whose diagnoses and treatment will be delayed."],"journal":"Colorectal Dis","authors":["Gunner, Charlotte K","Oliphant, R","Watson, Angus Jm"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32185863","week":"202012|Mar 16 - Mar 22","doi":"10.1111/codi.15043","source":"PubMed","weight":0,"_version_":1661633092440293376,"score":126.23862}]}